Arch Virol
- ALVAREZ-QUINTO R, Grinstead S, Kinard G, Martin R, et al
Complete genome sequence of vaccinium-associated virus C, a new member of the
family Totiviridae from Vaccinium floribundum.
Arch Virol. 2024;169:86.
BMC Pediatr
- KAMALI M, Navaeifar MR, Abbaskhanian A, Hajialibeig A, et al
Unusual presentation of miliary tuberculosis in a 12-year-old girl: a case
report.
BMC Pediatr. 2024;24:223.
BMJ
- DE OLIVEIRA ANDRADE R
After years of decline, Brazil sees vaccination coverage rise in 2023.
BMJ. 2024;385:q668.
- MAHASE E
Measles: South Sudan reports 12 000 cases in three months.
BMJ. 2024;384:q777.
Clin Infect Dis
- FAHERTY EAG, Holly T, Ogale YP, Spencer H, et al
Investigation of an mpox outbreak affecting many vaccinated persons in Chicago,
IL-March 2023-June 2023.
Clin Infect Dis. 2024 Apr 3:ciae181. doi: 10.1093.
- SU WJ, Chen HL, Chen SF, Liu YL, et al
Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration
of Maternal Screening and Infant Post-vaccination Serologic Testing.
Clin Infect Dis. 2024 Apr 2:ciae176. doi: 10.1093.
J Infect
- NG M, S D, L W, R B, et al
Paediatric meningitis in the conjugate vaccine era and a novel clinical decision
model to predict bacterial aetiology.
J Infect. 2024 Mar 27:106145. doi: 10.1016/j.jinf.2024.106145.
- MENGYANG G, Yahong H, Qinghong M, Wei S, et al
Resurgence and atypical patterns of pertussis in China.
J Infect. 2024;88:106140.
- MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or
frailty: the RAVEN cohort study.
J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
J Infect Dis
- TAIT D, Diacon A, Borges AH, van Brakel E, et al
Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in
adults successfully treated for drug-susceptible pulmonary TB: a phase 1
randomized trial.
J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093.
J Pediatr
- CLOPPER BR, Zhou Y, Tannis A, Staat MA, et al
Medical Costs of RSV-associated Hospitalizations and Emergency Department Visits
in Children Aged <5 years: Observational Findings from the New Vaccine
Surveillance Network (NVSN), 2016-2019.
J Pediatr. 2024 Mar 30:114045. doi: 10.1016/j.jpeds.2024.114045.
J Virol
- MANTEL N, Piras-Douce F, Chautard E, Marcos-Lopez E, et al
Cynomolgus macaques as a translational model of human immune responses to yellow
fever 17D vaccination.
J Virol. 2024 Apr 3:e0151623. doi: 10.1128/jvi.01516.
- BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2
spike protein brought to phase I/II clinical trials: candidate selection in a
preclinical murine model.
J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693.
- NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2
spike protein brought to phase I/II clinical trials: protection of African green
monkeys from COVID-19 disease.
J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762.
JAMA
- ANDERER S
CDC Recommends Additional COVID-19 Booster for Older Adults.
JAMA. 2024 Mar 13. doi: 10.1001/jama.2024.2071.
Lancet
- RAQIB R
Bivalent conjugate vaccines for typhoid and paratyphoid fever.
Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
- KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella
enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised,
active-controlled, double-blind trial.
Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
MMWR Morb Mortal Wkly Rep
- EL KALACH R, Jones-Jack N, Elam MA, Olorukooba A, et al
Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19
Vaccinations Across Sociodemographic Characteristics - United States, September
1, 2022-September 30, 2023.
MMWR Morb Mortal Wkly Rep. 2024;73:286-290.
- THOMAS CM, Hartley A, Schmitz A, Reid HD, et al
Implications of Measles Inclusion by Commercial Syndromic Polymerase Chain
Reaction Panels - United States, May 2022-April 2023.
MMWR Morb Mortal Wkly Rep. 2024;73:260-264.
Nat Med
-
Systematic testing in cholera surveillance enhances vaccine impact and
cost-effectiveness.
Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02907.
PLoS One
- THANGARAJ JWV, Prosperi C, Kumar MS, Hasan AZ, et al
Post-campaign coverage evaluation of a measles and rubella supplementary
immunization activity in five districts in India, 2019-2020.
PLoS One. 2024;19:e0297385.
- RICCI CONESA H, Skroder H, Norton N, Bencina G, et al
Clinical and economic burden of acute otitis media caused by Streptococcus
pneumoniae in European children, after widespread use of PCVs-A systematic
literature review of published evidence.
PLoS One. 2024;19:e0297098.
- ECHEVERRI TRIBIN F, Williams E, Testamarck V, Carreno JM, et al
Determinants of health as predictors for differential antibody responses
following SARS-CoV-2 primary and booster vaccination in an at-risk, longitudinal
cohort.
PLoS One. 2024;19:e0292566.
- MWANGI LW, Omuse G, Adam R, Ong'ete G, et al
Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and
non-clinical healthcare workers at a tertiary facility in Kenya.
PLoS One. 2024;19:e0299302.
- HERNANDEZ-BELLO J, Lorenzo-Leal AC, Munoz-Valle JF, Morales-Nunez JJ, et al
Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following
vaccination with Ad5-nCoV (CanSino) in the Mexican population.
PLoS One. 2024;19:e0299520.
- SILVA LA, Souza MF, Carvalho TP, Santana CH, et al
Comparative study on alginate/chitosan microcapsules and Montanide ISA 61 as
vaccine adjuvants in mice.
PLoS One. 2024;19:e0298117.
- FISMAN DN, Amoako A, Simmons A, Tuite AR, et al
Impact of immune evasion, waning and boosting on dynamics of population mixing
between a vaccinated majority and unvaccinated minority.
PLoS One. 2024;19:e0297093.
- AGIMAS MC, Belew AK, Sisay M, Daniel Baffa L, et al
Spatial variations and determinants of timely completion of vaccination in
Ethiopia using further analysis of EDHS 2019 data: Spatial and multilevel
analysis.
PLoS One. 2024;19:e0301409.
- THERESA POOL SN, Shroff EH, Chetty A, Lewis L, et al
Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against
COVID-19-associated hospitalisation and death in the Seychelles infected adult
population.
PLoS One. 2024;19:e0299747.
Vaccine
- PADENIYA TN, Hui BB, Wood JG, Regan DG, et al
Review of mathematical models of Neisseria gonorrhoeae vaccine impact:
Implications for vaccine development.
Vaccine. 2024 Mar 30:S0264-410X(24)00380-3. doi: 10.1016/j.vaccine.2024.
- HUF SW, Grailey K, Crespo RF, Woldmann L, et al
Testing the impact of differing behavioural science informed text message content
in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical
trial.
Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
- MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
Effectiveness of COVID-19 vaccination against school absenteeism in children and
adolescents hospitalized with COVID-19.
Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
- GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
Self-reported determinants of COVID-19 vaccine acceptance among persons with and
without autoimmune disease.
Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
- KIMBUGWE G, Vatrinet R, Mwanga JA, Kakuru R, et al
Perceptions, attitudes, and willingness of healthcare and frontline workers to
participate in an Ebola vaccine trial in Uganda.
Vaccine. 2024 Apr 1:S0264-410X(24)00358-X. doi: 10.1016/j.vaccine.2024.
- TEMBO G, Mayuni M, Kamng'ona R, Chimgoneko L, et al
Poor association between 13-valent pneumococcal conjugate vaccine-induced serum
and mucosal antibody responses with experimental Streptococcus pneumoniae
serotype 6B colonisation.
Vaccine. 2024 Apr 2:S0264-410X(24)00360-8. doi: 10.1016/j.vaccine.2024.
- NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine
(IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3,
randomized, active-controlled, multicenter trial.
Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
- HEISLER-MACKINNON JA, Queen T, Yi Kong W, Kennedy KL, et al
Identifying effective vaccine champions: Findings from a national survey of
primary care professionals.
Vaccine. 2024 Apr 3:S0264-410X(24)00403-1. doi: 10.1016/j.vaccine.2024.
- ALTAWALBEH SM, Wateska AR, Nowalk MP, Lin CJ, et al
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal
conjugate vaccine in US adults aged 50 years or older.
Vaccine. 2024 Apr 4:S0264-410X(24)00404-3. doi: 10.1016/j.vaccine.2024.
- BAUM HE, Thirard R, Halliday A, Baos S, et al
Detection of SARS-CoV-2-specific mucosal antibodies in saliva following
concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
- SCHULTZE A, Martin I, Messina D, Bots S, et al
A comparison of four self-controlled study designs in an analysis of COVID-19
vaccines and myocarditis using five European databases.
Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016